Neoantigen Vaccine for Melanoma Reaches Beyond Its Target

Source: Cancer Therapy Advisor, March 2021

A personalized, long-peptide vaccine that can target up to 20 personal neoantigens per patient has been successful in preventing melanoma in patients at high risk for recurrence, according to the findings of a phase 1 study published in Nature Medicine.1 The vaccine helps the body mount a robust response to the disease by training a patient’s immune system to recognize and attack cancerous signals, with increasing detection over time.

READ THE ORIGINAL FULL ARTICLE

 

Menu